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ABSTRACT
Introduction Chronic lower back pain is a highly 
prevalent medical condition in Western countries, which 
that incurs a considerable social and economic burden. 
Although prescription exercise at home for chronic pain 
has become a widely used alternative to reduce healthcare 
costs, the evidence regarding patient adherence and 
decreased in costs in European countries is scarce and 
inconclusive. The objective of this study is to examine the 
cost–utility and cost- effectiveness in patients with chronic 
lower back pain treated with the McKenzie Method and 
electroanalgesia via a telemedicine programme versus a 
face- to- face programme.
Methods and analysis This study reports the protocol 
for a randomised, two- arm, multicentre, parallel controlled 
trial. A total of 540 patients with chronic lower back 
pain (onset time ≥3 months, Roland Morris Disability 
Questionnaire ≥4) will be recruited in three hospitals in 
Andalusia. Participants will be assigned to one of two 
groups (n=270, respectively) to receive electroanalgesia 
and Mckenzie method exercises through a telemedicine 
or a face- to- face programme. A total of 24 sessions will 
be administered three times a week for 8 weeks. Since 
the study design does not allow participant blinding, the 
outcome assessor and the statistician will be blinded. Use 
of helth care resources and costs due to work absenteeism 
will be captured and analysed. In addition, pain, intensity, 
fear of movement, quality of life and strength of the core 
muscle and anteflexion lumbar will be recorded at 2 and 6 
months after the start of treatment.
Ethics and dissemination Human Research and Local 
Ethics Committee of the ‘Hospital Complex Torrecárdenas 
of Almeria, University Hospital of Granada and Virgen 
Macarena de Sevilla Hospital—Andalusian Health Service’. 
Study findings will be released to the research, clinical and 
health service through publication in international journals 
and conferences.
Trial registration number NCT04266366.
INTRODUCTION
Dysfunctions that affect the spine are the 
most frequent cause of activity limitation 
in people under 45 years of age, with lower 
back pain (LBP) being the most common 
cause of disability in the occupationally active 
population.1
Most patients experiencing LBP that limits 
activity have recurrent episodes, with estimates 
ranging between 24% and 33%.2 Different 
studies have shown that 42%–75% of patients 
with intermittent LBP that persists after 12 
months represent the highest expenses in 
healthcare systems and disability, being one 
of the main causes of consultation in hospital 
emergency services.3–5 It has been estimated 
that the direct economic cost associated with 
LBP in Europe ranges from 187 million to 
4.2 billion euros in the Netherlands.6
Strengths and limitations of this study
 ► This protocol describes a randomised controlled trial 
of a telemedicine intervention for primary care pa-
tients with chronic lower back pain who are on the 
waiting list for rehabilitation.
 ► The use of the Internet to carry out the intervention 
may exclude some primary care patients who live 
in rural areas or who do not have the financial re-
sources to use it.
 ► This study will explore the possibility of additional 
telephone support from the physiotherapist to im-
prove adherence of the intervention.
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The alterations of the motor control of the deep local 
muscles of the lumbopelvic region and persistent arthro-
genic muscle inhibition of lumbar multifidus result in 
segmental instability of the lumbar spine and, conse-
quently, in recurrent back pain.7–12 If the alterations in 
one or more of the spine’s stabilising mechanisms do not 
resolve during the acute period, tissue damage is caused 
that causes LBP persist.8 Numerous studies have shown 
that specific exercises aimed at local lumbar muscles 
result in improvements in pain and disability, as well as 
a lower incidence of recurrence and absenteeism in the 
chronic LBP population.12–18 Nonetheless, these exer-
cise programmes are relatively expensive, require a lot 
of time from the patient and the therapist, and most do 
not use diagnostic tests to identify those patients who will 
benefit from one type of exercise or another in advance. 
Although exercise is the most commonly recommended 
treatment for patients with chronic LBP, clinical practice 
guidelines recommend many other interventions.19 20
Some authors have even compared this to a super-
market, since, in addition to being endless, treatment 
options are becoming more comercial and competitive 
every day.21
Transcutaneous electrical nerve stimulation (TENS), 
alone or in combination with other interventions, is 
one of the most common techniques for pain relief in 
chronic LBP.22–26 Some studies have shown that TENS 
can lead to decreased use of pain medications and should 
be incorporated into the treatment arsenal for chronic 
LBP.22 In spite of this, there is some controversy in the 
clinical evidence about its use as the only treatment in 
chronic LBP.19 26 27 According to Gladwell et al,27 training 
in the use of equipment (electrode placement and TENS 
adjustments) could improve the clinical benefit provided 
by TENS.
Self- management is constantly recommended in the 
international guidelines on the management LBP.24 27 
Home exercise programmes based on self- managing LBP 
can be effective in avoiding recurrent LBP and reduce the 
reliance on, and cost of, primary care services.28 However, 
studies have shown that adherence to prescribed exer-
cises at home in patients with LBP is low, with 50%–70% 
of patients not adhering to the prescribe exercise 
routine.29 30 A systematic review has highlighted that the 
most commonly cited reasons that prevent patients incor-
porating the exercises into their daily routine include the 
lack of time to perform the exercises and the inability to 
remember them.31
It is, therefore, essential to look for alternative models 
of health service delivery that can improve treatment 
adherence in patients with chronic LBP and, as a result, 
enable increased uptake and implementation.
The self- management approach of exercise based on 
the McKenzie method (of Mechanical Diagnosis and 
Therapy, MDT) plus TENS through digital applications 
can be an effective alternative to traditional models. It has 
been shown that e- Health treatments enable personalised 
medical attention at a distance through digital applications 
such as mobile phones, which is promising in terms of 
effectiveness and profitability in improving results such 
as: patient health and satisfaction, self- control of symp-
toms (improves understanding of treatment and allows 
the patient to get involved in their self- management) 
and the costs of medical care in patients with chronic 
diseases.32–34 In addition, MDT has been shown to have 
important advantages over the general exercises and 
other interventions for chronic LBP.35–38
Aims of the study
The study aims to assess the cost- effectiveness and 
cost–utility of an MDT- based telemedicine programme 
with electroanalgesia and self- administered exercises 
compared with the same programme delivered face to 
face in patients with chronic LBP.
Specif objectives are: (1) to assess the mean per- patient 
cost associated with the two delivery options, (2) to 
compare the effectiveness of both interventions, in terms 
of disability, pain intensity, movement phobia, quality of 
life, isometric resistance of the flexor muscles of the trunk, 
lumbar mobility in flexión and (3) to calculate and report 
incremental costs and benefits associated with delivering 
the intervention through telemedicine compared with 
face- to- face administration.
Trial design
This study is a two- arm, double- blind, multicentre, 
randomised controlled trial.
METHODS/DESIGN
Study design and study setting
Cost- effectiveness and cost–utility analysis (CUA) of 
a multicentre randomised clinical trial protocol that 
compares patients with chronic non- specific LBP treated 
with a telemedicine programme, with a control group 
participating in face- to- face programme. The study partic-
ipants will be randomly allocated to one of two groups 
(the telemedicine group or control face- to- face group) 
with a ratio of 1:1. This protocol is reported in accor-
dance with the Standard Protocol Items: Recommenda-
tions for Interventional Trials 2013 statement (online 
supplemental additional file 1). The study is conducted 
in collaboration of the physiotherapy department of 
the University of Almeria. Ethical approval for this trial 
was granted by the Human Research and Local Ethics 
Committee of the ‘Hospital Complex Torrecárdenas of 
Almeria, University Hospital Complex of Granada and 
Virgen Macarena de Sevilla Hospital—Andalusian Health 
Service’/Almeria University, Andalucia, CE- IP00562/
NCT04266366.
We contacted three Primary Healthcare Centres (PHCC) 
of Andalucia (Spain), in the provinces of Almeria, Sevilla 
and Granada, presented the study to their staff members 
and invited them to participate. Patients who received 
an indication for outpatient rehabilitation treatment 
at any of the three PHCC, will be selected from March 
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2020 to May 2020 (anticipated), based on the eligibility 
criteria listed below. The potentially eligible subjects will 
be invited to participate via a text message after informed 
consent is obtained by the hospitals’ staff members (phys-
iotherapists and general practitioners (GPs)).
A total of 540 participants with diagnosed chronic non- 
specific LBP will be recruited. Participants will receive 
treatment three times per week over a period of 8 weeks 
in the outpatient department or at home, with follow- up 
assessment at 2 and 6 months after start of treatment. 
On their first visit, participants will be selected for study 
eligibility according to the study’ inclusion and exclusion 
criteria, and will be evaluated by a therapist blinded to 
the intervention in each PHCC. After this face- to- face 
evaluation, patients will be randomly assigned to one of 
the two groups, and will be informed by message about 
their second visit (place and time). From the second visit, 
participants will receive treatment for LBP according 
to their random assignment group by two therapists 
belonging to the research group and trained in MDT 
(schedule of enrolment, interventions and assessments is 
provided in figure 1).
Patient and public involvement
Patients and the public were not involved in designing 
this protocol and statistical analysis plan. The GPs and 
physiotherapists of the hospitals where the study will be 
carried out will provide support for recruitment. The 
results of the study will be disseminated to the public on 
completion of the trial and the individual test results will 
be provided to participants on request.
Participants
Inclusion criteria
 ► Patients age 30–67 years old.
Figure 1 Design and flow of participants through the trial. ODI, Oswestry Disability Index; PHCC, Primary Healthcare Centres; 
QALYs, quality- adjusted life year; RMQ, Roland- Morris Questionnaire; SF-36, Short- Form Health Survey 36; TSK, Tampa Scale 
of Kinesiophobia; VAS, Visual Analogue Scale.
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 ► Patients with chronic LBP (pain duration of ≥3 
months).
 ► Patients who have a lower back disability ≥4 on the 
Roland- Morris Disability Questionnaire (RMDQ).
 ► Patients currently not receiving any other physio-
therapy treatment.
Exclusion criteria
 ► Patients diagnosed with severe pathologies that may 
be the main cause of chronic LBP (eg, presence of 
lumbar stenosis, spondylolisthesis, fibromyalgia, etc).
 ► Patients who have taken treatment with corticoster-
oids or oral medication in recent weeks.
 ► Patients with a medical history of spine surgery.
 ► Patients who do not have contraindicated of analgesic 
electrical therapy.
 ► Patients who have previously received a treatment of 
electrical analgesia or exercise.
 ► Patients with severe concurrent central or peripheral 
nervous system disease.
Randomisation and allocation concealment
Subjects will be divided into two groups by means of a 
random number table generated by computer software 
(Epidat V.4.2). The randomisation will be conducted 
for each study site. On randomisation within each study 
site, participants will be allocated to either the control or 
experimental group according to the allocation code, and 
the number of participants in each group will be identical 
between groups for all study sites. The randomisation 
sequence will be performed by the principal investigator.
The number of participants for each study site will be 
90. The results of random allocation will each be sealed 
in opaque envelopes before being sent to each study site 
and will be stored in double lock cabinets.
The random numbers assigned to each participant will 
be recorded in the electronic records of their medical 
history and patients will be removed from the waiting lists 
until the end of the study (figure 1).
Blinding
The study’s outcome assessor and statistician will be 
blinded for the entire process. The outcome assessor 
will not take part in treatment and will not try to guess 
the treatment allocation group to which the participant 
may be allocated. The computerised outcome measures 
passed on to the statistician will not contain any infor-
mation identifying patients as part of either of the two 
groups.
Interventions
After the initial evaluation, 540 patients with chronic LBP 
will be randomly assigned to two groups in each PHCC: 
electroanalgesia therapy and exercise through a telemed-
icine programme (experimental group) or the same care 
delivered through a face- to- face programme (control 
group). Within both groups, these patients will be 
divided into three subgroups (postural, dysfunction and 
derangement) according to the McKenzie therapeutic 
classification (clinical presentation of pain). All partic-
ipants will receive three sessions per week, to complete 
a total of 24 sessions. The treatment will be carried out 
on alternate days: Mondays, Wednesdays and Fridays. 
Patients will have to perform 90% of their scheduled 
treatment sessions to be considered and remain in the 
intention- to- treat analysis.
During the study, the participants can only receive the 
assigned treatment; they cannot combine the treatment 
with drugs or any other treatments. Any interference in 
the treatment will be grounds for exclusion. Patients can 
leave the study at any point and the allocated interven-
tions will be modificated for a given participants of trial 
in response to the improvement or deterioration of LBP. 
Aspects such as execution time, level of difficulty, inten-
sity and progression will adjust individually.
The exercise programme is as follows:
1. Prone position: patient lying prone with the arms by 
their sides and their head lying on either side. The 
lumbar spine falls directly into the lordotic position 
(time: 60 s).
2. Prone position in extensión: the elbows are just below 
the shoulders, patient raises the upper part of their 
torso, resting on their forearms (time: 60 s).
3. Extension in prone position: the patient is lying in a 
manner similar to the previous exercises. Hands at 
shoulder level. Extending the arms raises the upper 
part of the torso. Then the patient lowers their torso 
(10 times).
4. Prone extension with fixation of the pelvis: position 
and movements equal to 3. A fixation is made with an 
exercise belt just at the level of the pelvis (10 times).
5. Sustained extension in recumbency: patient lying 
prone on a surface that allows the degree of torso 
extension to be passively increased. Returning to the 
horizontal position should be done slowly and pro-
gressive way (time: 2–10 min).
6. Extension stopped in standing position: patient 
standing with feet apart, hands on waist with fingers 
pointing down. Extends by using the hands as the ful-
crum of the movement (5–10 times).
7. Supine flexion: patients bring both legs flexed to the 
chest (time: 30 s).
8. Seating flexion: from the seated position, patient 
brings their hands to their feet (10 times).
9. Flexion stopped in standing position: patient touches 
the floor with their fingers, keeping their knees ex-
tended (10 times).
10. Autocorrection of lateral displacement: ‘push in dis-
traction’. The shoulders push towards the pain and 
pelvis on the opposite side (time: 30–60 s).
Simultaneously with the performance of the exercises: 
TENS (TENStem eco basic, schwa- medico Medizinische 
Apparate Vertriebsgesellschaft mbH, Wetzlarer/35630/
Ehringshausen, Deutschland) of low frequency and high 
phase duration (80 Hz / 200 μs) applied directly to the 
lower back using four electrodes (5×9 cm) at the bilateral 
paravertebral level.
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Experimental group: telemedicine
During the first two sessions, patients will be instructed 
in the placement of the electrodes, the operation of the 
TENS, the ‘Stop LBP’ web application and the perfor-
mance of the exercises. After the two session, the patient 
will carry out the treatment through a support system for 
the treatment of chronic LBP based on Web Technolo-
gies and accredited as a health website. This system has 
a structure based on four sections: database treatment, 
database user profiles, recommendations and feedback/
biofeedback procedures. This system allows a subject to 
be registered and introduced and treatments to be modi-
fied with electroanalgesia and exercises, according to the 
symptomatic evolution of pain.
This is based on an initial patient evaluation system: 
once the initial diagnosis of the patient has been made 
according to McKenzie’s clinical subtypes of LBP, the 
video applications of the combined application, the elec-
troanalgesia and exercises, will be shown to patients who 
use their computer or mobile device to access the plat-
form via the internet.
The treatments will be recommended by the system: 
the database is configured to accommodate the applica-
tion of electroanalgesia and McKenzie exercises based on 
the diagnosis according to the McKenzie method. Each 
subgroup corresponds to a programme and a series of 
exercises based on scientific evidence for the treatment 
of LBP39 40:
 ► Postural syndrome: correction of posture and prophy-
laxis (exercises 1–3).
 ► Dysfunction syndrome: exercise 3, exercise 6 and 
exercise 7.
 ► Disorder syndrome (DS): DS1 (exercises 1–4, exer-
cise 6, with extension in recumbency); DS2 (begin-
ning in prone position and patients will continue 
with the DS1 regimen, along with exercise 5); DS 3 
(DS1 regimen, exercise 7 and rotation maintained 
for 2 min); DS4 (exercise 7, exercises 2 and 3, and 
DS1 regimen); DS5 (exercises 7 and 8, and exercise 
1–3); DS6 (DS4 regimen; then DS1 and DS3); DS7 
(exercises 7–10).
During the first two sessions, patients will also be 
instructed in the use of a portable TENS.
Patients perform the exercises with the electrodes on.
To ensure patient adherence, inputs to the application 
and the time they spend on it each login are controlled. 
In addition, participants in both groups are called every 
2 weeks to remind and encourage them to perform the 
exercises.
Control group: face-to-face programme
This group performs the same treatment but in person. 
Electroanalgesia therapy and the McKenzie exercise 
protocol will be applied by six therapists with over 10 
years of experience (two therapists in each PHCC). This 
programme will be developed in the rehabilitation service 
of the study health centres.
Outcome measures
At baseline, demographic data including age, gender, 
education, occupational and marital status and clinical 
presentation will be documented. Assessments will be 
performed at baseline (before start of treatment) and at 
2 (immediately after the last session) and 6 months after 
the last session (follow- up).
Effectiveness and quality of life measures
Most of these measures are specific for LBP, and this 
have been validated for this pathology, which is a suffi-
cient source of data to evaluate the clinical efficacy of 
the applied interventions. The primary effectiveness 
measures of the study consist of:
Roland Morris Disability Questionnaire
This is a self- reported questionnaire consisting of 24 
items reflecting limitations in different activities of daily 
living attributed to LBP, including walking, bending 
over, sitting, lying down, dressing, sleeping, self- care and 
daily activities. Ranging from 0 points (best) to 24 points 
(worst) disability.41
Oswestry Disability Index
The Oswestry Disability Index (ODI) evaluates daily 
life activity limitations in 10 dimensions, each scored 
on a 6- point scale (0–5 points). Higher scores mean a 
worse outcome; the total points scored are expressed as 
a percentage, used to classify individuals as minimally 
disabled (0%–10%), moderately disabled (20%–40%), 
severely disabled (40%–60%), crippled (60%–80%) or 
bedbound (80%–100%).42
Visual Analogue Scale for pain
The subjects participating in the study will indicate the 
intensity of their pain by means of a Visual Analogue 
Scale (VAS) of 100 mm. They must indicate on a 100 mm 
horizontal line where they would place their pain, where 
0 mm indicated ‘no pain’ and 100 mm would be ‘the worst 
pain imaginable’.43
Short-Form Health Survey 36 Quality of Life Qquestionnaire
The Short- Form Health Survey 36 (SF-36) is a multipur-
pose, SF-36 questions. The instrument yields an eight- 
scale profile of scores as well as physical and mental 
health summary measures: Physical Function, Physical 
Role, Body Pain, General Health, Vitality, Social Func-
tion, Emotional Role and Mental Health. Range from 0% 
to 100% and indicate the self- perceived health- related 
quality of life.44 45
EuroQol 5-dimension-5 level
The EuroQol 5 dimensions (EQ- 5D) is a widely recom-
mended generic measure of health- related quality of 
life that enables the calculation of quality- adjusted life 
years (QALYs).46 47 The study will use the latest, five- level 
versión of the questionnaire (EQ- 5D- 5L). The descriptive 
part of the EQ- 5D- 5L questionnaire comprises questions 
on mobility, self- care, usual activities, pain/discomfort, 
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anxiety/depression, each of which can be answered in 
relation to five levels of severity and is accompanied by 
a VAS.48 Collected data from the EQ- 5D- 5L descriptive 
system will be subsequently translated into preference- 
based health- related quality of life indices (utilities) using 
the recommendeda Spanish value set,49 with a view to 
using these índices in the calculation of QALYs.
Tampa Scale of Kinesiophobia
This is a 17- item questionnaire that measures the fear of 
movement and (re)injury. Patient rate beliefs about their 
kinesiophobia on a 4- point scale ranging from strongly 
disagree to strongly agree.50 51
McQuade test
This test allows to evaluate the isometric resistance of the 
trunk flexor muscles. In the supine position, the subject 
is asked to flex the head and shoulders until the scapula is 
separated from the stretcher. The number of seconds that 
hold that position is recorded.52
Lumbar flexion mobility (Fleximeter UM 8320-3RJ)
With the legs extended, patients are asked to do an ante-
rior torso flexion from an upright position to try to touch 
the ground. The patient should stop when pain or limita-
tion of movement appears.53
Resource use and costs measurement
Key healthcare resource use and costs will be collected 
alongside the proposed trial through patient question-
naires administered at baseline, and subsequently, at the 2 
and 6 months follow- up points. A detailed list of relevant 
resource use categories, sources of usage data and unit 
costs is given in table 1. In brief, relevant resource use and 
costs will include those incurred due to care received in the 
primary care and hospital settings, costs accruing due to 
diagnostic tests, as well as other costs incurred to patients 
(eg, out- of- pocket expenditures for transportation) and 
to society due to absenteism resulting in productivity loss. 
Information on the resource consumption of each partic-
ipant will be collected through an inventory of receipts. 
For each follow- up session (at the beginning and at 2 and 
6 months after the beginning), participants will be asked 
to recall their use of the resources described above during 
the preceding months. Use of healthcare resources will be 
converted into costs according to unit cost values taken 
from up- to- date sources including the Andalusian Board 
for the public health services (see table 1).
Timeline
The recruitment of patients started on 1 March 2020 
and will be completed by 31 May 2020. All data for all 
Table 1 Self- reported cost measurements







Andalusian health service provider No of visits×tariff per visit
Hospital emergency visits GP
Practice nurse
Andalusian health service provider No of visits×value per visit




Andalusian health service provider Services provided×tariff per 
visit
Home help received Ambulance
GPs
Practice nurse
Andalusian health service provider Services provided×tariff per 
services
Diagnostic tests Radiology, MR, scanner, 
electromyogram
Andalusian health service provider Tests done×price per test
Pharmaceutical products Muscle relaxants, analgesics, 
NSAIDs, corticoids, anti- 
inflammatory creams and 
gastric protectors
Standard pharmaceutical prices 




Non- medical direct costs





Patient No of times×price per time
Indirect costs
Absenteeism Days of work sick leave Self- reported and according to 
profession classification assigned 
(Spanish National Institute of 
Statistics)
Days of work sick 
leave×salary
NSAIDs, Non- steroidal Anti- inflammatory Drugs.
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follow- up sessions is expected to be collected before to 
31 July 2020. The data analysis, writing of scientific manu-
scripts and submissions to peer- reviewed scientific jour-
nals will be carried out between August 2020 and January 
2021. A summary of the study outline is given in figure 2.
Sample size
The sample size was calculated according to the speci-
fications established by Willian.54 The calculations were 
based on the detection of differences of 2.5 points in the 
RMDQ (minimally detectable mean difference- estimated 
for a variance in patients with chronic LBP of 10 points), 
assuming a SD of 2.5 points, a two- tailed test, an alpha (α) 
level of 0.05 and a desired potency (beta) of 85%. The 
estimated desired sample size has been calculated in 270 
subjects per group (6 groups per 90 subjects).
On the other hand, the following specifications will 
be considered: correlation coefficient between effi-
ciency and cost of 0.1, α=0.05, statistical power of 85% 
and follow- up loss of 10%. The sample size calculation 
resulted in 93 participants that will be randomly allocated 
into six intervention groups (an experimental group and 
a control group in each PHCC).
Statistical analysis
The statistical analysis will be carried out using SPSS 
V.21.0 and STATA V.14, it will follow intention- to- treat 
principles. Cost, clinical outcomes measures and use of 
resources will be reported as mean values with SD for each 
intervention arm. Comparisons will be done between 
arms on the study population’s.
Differences after 8 weeks of treatment will be calculated 
(short term outcomes), as well as after 6 months (long- 
term outcomes).
The efficacy variable for this clinical trial is the difference 
in continuous outcomes (ie, RMDQ, ODI, VAS, Tampa 
Scale of Kinesiophobia, EQ- 5D- 5L, SF-36, McQuade Test 
and Range of motion of the torso in flexion) between 
baseline and predetermined time points (Telemedicine 
programme vs face- to- face programme):
 ► The Kolmogorow- Smirnov test will be carried out to 
assess the normality of each continuous variable.
 ► For the contrast of the equality of means of intra-
group hypotheses, Student’s t- test for paired clinical 
variables will be applied in the case of parametric 
distributions and Kruskal- Wallis H for nonparametric 
distributions.
 ► For the contrast of the intergroup hypothesis, one- 
factor analysis of variance will be used in the case 
of parametric distributions and Kruskal- Wallis H for 
non- parametric distributions.
 ► Post hoc analysis will be obtained for parametric distri-
butions and Mann- Whitney’s U for non- parametric 
distributions.
 ► The CI will be established at 95%, and the significance 
level at 0.05.
Economic evaluation
An economic evaluation, in the form of a CUA and a 
cost- effectiveness analysis (CEA) will be undertaken to 
explore and determine the incremental costs and bene-
fits of the telemedicine and face- to- face programmes over 
a 6- month time horizon. This follow- up period aims to 
capture the direct effects of the interventions and offer 
insights into outcomes and costs accruing in the months 
after the intervention is completed. In line with recom-
mendations, the economic evaluation will adopt a societal 
perspective.55
Missing cost or outcome data will be accounted for by 
using appropriate techniques, such as multiple imputa-
tion, depending on the extent and type of missing items. 
As the distribution of cost is usually skewed by the exis-
tence of patients with very high costs, the calculated 
mean per- patient cost will be given alongside confidence 
intervals obtained through non- parametric bootstrap 
methods.56 Incremental analysis will be undertaken to 
calculate the difference in costs and the difference in 
outcomes (improvementsn in effectiveness measures and 
QALYs) associated with the telemedicine and face- to- face 
programmes. QALYs will be calculated as the area under 
the curve connecting utility scores reported at baseline 
and the subsequent follow- up points. Results will be 
presented in the form of incremental cost- effectiveness 
ratios, reflecting the extra cost for an additional unit of 
outcome. To account for the inherent uncertainty due to 
sampling variation, the joint distribution of differences 
in cost and outcomes will be derived by carrying out a 
Figure 2 Time points of each assessment index. EQ- 5D, 
EuroQol 5 dimensions; ODI, Oswestry Disability Index; 
RMDQ, Roland- Morris Disability Questionnaire; SF-36, Short- 
Form Health Survey 36; TSK, Tampa Scale of Kinesiophobia; 
VAS, Visual Analogue Scale.
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large number of non- parametric bootstrap simulations.57 
The simulated cost and outcome pairs will be depicted 
on a cost- effectiveness plane and will be plotted as cost- 
effectiveness acceptability curves, showing the probability 
of each of the compared options being cost- effective 
across a range of possible values of willingness to pay for 
a QALY.58 Different willingness to pay threshold values 
for a QALY have been put forward and used in cost- 
effectiveness studies59; in the Spanish context, recent 
estimates suggest a cost per QALY willingness to pay 
threshold between €22 000 and €25 000.60 Sensitivity 
analysis will be performed to assess the robustness of 
the results to different values, assumptions and method-
ological approaches.61 Due to the short time horizon of 
the study, discounting of costs and benefits will not be 
necessary. The CEA will be reported in accordance with 
the Consolidated Health Economic Evaluation Reporting 
Standards.62
Adverse events
Adverse events refer to undesirable and unintentional 
signs, symptoms or disease occurring after treatment 
during the process of the clinical trial, which does not 
have to have a causal relationship with the treatment 
intervention.
At present, no potential risks have been described. The 
electroanalgesia to be applied is low risk, no adverse reac-
tions have been described beyond the discomfort in the 
placement of the electrodes.
As for the exercises, all are proposed after evaluation 
and adaptation to the patient’s situation, therefore, the 
potential risks are only associated with poor execution by 
the patient, which could cause short- term and reversible 
discomfort within 48 hours.
Investigators will be recorded all description of adverse 
events. If these exist, occurrence frequency between 
groups will be analysed. Any patient with questions or who 
require additional information about any symptoms can 
contact the AMC- S coordinator by telephone or email.
Ethics, data security and dissemination
This study was approved by the Human Research and 
Local Ethics Committee of the ‘Hospital Complex 
Torrecárdenas of Almeria, University Hospital of Granada 
and Virgen Macarena de Sevilla Hospital—Andalu-
sian Health Service’/Almeria University, Andalucia, 
CE- IP00562/NCT04266366.
All patients, GPs and physiotherapists will receive 
specific information on the study in writing and will have 
a chance to discuss procedures with a member of the 
study team before consenting to take part. They will also 
be informed that they can leave the study at any point. 
Participants that agree to participate in the study will sign 
two copies of the informed consent, one that will be kept 
in the trial records and one for the participant.
The data collected from each patient will be stored in 
a closed locker in office of the University of Almeria and 
only the evaluators will have access to that information. 
Subsequently, the data will be entered and saved by the 
statistician on a laptop with password protection to main-
tain confidentiality. Eligibility criteria, results and anal-
ysis will not be modified after registration of the first 
participant.
The results will be published in journals indexed in 
Journal Citations Report and presented at national and 
international conferences.
DISCUSSION
While exercise has proven to be the physical therapy 
treatment that has the most positive and lasting effects 
on chronic LBP,63 64 the results of the analgesic effect 
of TENS in these patients have been contradictory 
depending on the duration, dose.65 66 Therefore, new 
research is required to evaluate the specific components 
of the treatments used by the therapist, by comparing 
their use combined with the CUA.
Some studies have suggested a high social acceptance 
and confidence of patients towards telehealth in trauma 
care, especially for real- time diagnosis and remote 
treatment.67 Through this study, we can contribute to 
a better understanding of the cost- effectiveness of tele-
medicine programmes versus fase- to- face rehabilitation 
programmes in patients with chronic LBP in the short 
and medium term. The results of this study can help 
GPs and physiotherapists to understand if LBP can be 
prevented and treated at home through telemedicine, 
thereby reducing family and absenteeism costs signifi-
cantly for these patients.
Through these remote interventions via the Internet, 
patients can learn to control the evolution of their LBP, 
by preventing its evolution to stages of greater pain 
and disability. If the painful symptomatology improves 
without having to cease work activity, the worker’s labour 
and productivity costs are reduced, along with healthcare 
costs and waiting lists for the rehabilitative therapeutic 
approach, thereby favouring greater savings.
In addition, the specific e- Health and telemedicine 
programmes implemented in the evaluation and treat-
ment of musculoskeletal problems can reduce health 
costs, generate a significant impact on patients living 
in rural or remote areas and increase adherence to 
treatment.
Trial status
This is the first and definitive protocol version. Partici-
pants will be recruited between March and May 2020. 
Study completion is expected to be January 2021.
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